Drug delivery systems

-



 Drug delivery systems refer to technologies and approaches used to deliver pharmaceutical compounds to specific targeted sites within the body in a controlled manner. These systems are designed to improve the efficacy and safety of drugs by ensuring optimal drug concentration at the target site while minimizing side effects and reducing dosing frequency.

There are several types of drug delivery systems, each with its own advantages and applications:

  1. Oral Drug Delivery: The most common route for drug administration, involving tablets, capsules, or liquids that release drugs in the gastrointestinal tract.

  2. Injectable Drug Delivery: Includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections, allowing for rapid drug delivery and precise dosing.

  3. Transdermal Drug Delivery: Delivers drugs through the skin via patches or topical formulations, providing sustained release and avoiding first-pass metabolism.

  4. Inhalation Drug Delivery: Delivers drugs directly to the lungs through inhalers or nebulizers, used for respiratory conditions or systemic drug delivery.

  5. Implantable Drug Delivery: Involves devices implanted under the skin or in tissues to release drugs over an extended period, such as contraceptive implants or drug-eluting stents.

  6. Nanoparticle-Based Drug Delivery: Uses nanoparticles to encapsulate drugs, improving solubility, stability, and targeting specific tissues or cells.

  7. Targeted Drug Delivery: Utilizes ligands or antibodies to target specific cells or tissues, reducing systemic side effects and enhancing drug efficacy.

  8. Microsphere Drug Delivery: Uses microspheres (small spherical particles) to encapsulate drugs, controlling release rates and improving bioavailability.

Advantages of advanced drug delivery systems include improved patient compliance, enhanced therapeutic outcomes, reduced side effects, and potential cost savings due to lower doses or reduced hospitalizations.

null


Comments

Post a Comment

Popular posts from this blog

Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial

-
Image
Sanofi’s Sarclisa (isatuximab) plus standard of care has been shown to extend the time that some multiple myeloma patients remain stable without disease progression. This was demonstrated in a Phase III trial (NCT03617731) with 662 newly diagnosed patients who were eligible for a stem cell transplant. The trial found that adding Sarclisa to the standard drugs – lenalidomide, bortezomib, and dexamethasone (Rvd) – resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy. Sanofi said that these results reinforce the potential of Sarclisa as a backbone therapy when added to the current standard of care in various multiple myeloma patient populations. These recent findings build on data from 2021, where the trial met a different primary endpoint of minimal residual disease (MRD) negativity after induction therapy and before transplant. Around 50.1% of the newly diagnosed multiple myeloma patients achiev...
Read more

MDMA Papers Retracted for ‘Unethical Conduct’ on Heels of Lykos’ FDA Rejection

-
Image
A day after the regulator denied approval of Lykos’ MDMA-assisted PTSD therapy, a medical journal pulled three studies related to the use of the psychedelic in the indication. The medical journal Psychopharmacology on Saturday retracted three papers related to the use of the psychiatric substance MDMA for the treatment of post-traumatic stress disorder. The decision to pull the studies was driven by “protocol violations amounting to unethical conduct” at one of the study sites, according to the journal’s retraction note. The authors of the studies also confirmed to Psychopharmacology that they knew of these breaches when they submitted their manuscript “but did not disclose this information to the journal or remove data generated by this site from their analysis.” Many of the authors failed to fully disclose a “potential competing interest, ” according to the retraction notice, while some of the researchers were affiliated with either the Multidisciplinary Association for Psychedelic...
Read more

Cell and gene therapy companies must demonstrate strong value proposition for investment

-
Image
Investment for companies developing cell and gene therapies (CGTs) was discussed during the GenScript Biotech Global Forum London 2024 conference held on 20 November 2024. Following a sharp drop in CGT investment in 2022, trends suggest that CGT investment is currently undergoing a “renormalisation”. However, investors continue to be selective, said speakers Josh Resnik, senior managing director at RA Capital Management, and Ping Shek, managing director at Stifel’s Healthcare Investment Banking Division. CGTs have faced challenges attracting investment due to the large amount of capital required to manufacture CGTs, as well as hurdles relating to reimbursement of one-off, high-cost therapies and patient access. Resnik noted that investor sentiment about CGTs was impacted by competitive pressures from “not-so-complicated biologics” such as antibody-drug conjugates, radiopharmaceuticals, and T-cell engagers in oncology and immunology. Resnik noted that CGTs must demonstrate a stron...
Read more